tbuckley/cabot-search huggingface dataset:
Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia
Authors: M. M. Bortin
Journal: JAMA (1981)

Comprehensive data were reported to the International Bone Marrow Transplant Registry by 24 worldwide teams regarding 144 patients with severe aplastic anemia who were treated with HLA-identical, allogeneic bone marrow transplantation between 1975 and 1978. One hundred fourteen patients received one transplant and 30 received two. Sustained engraftment of donor marrow occurred on the first transplant attempt in 76% of the patients whose engraftment status could be evaluated. Moderate, severe, or lethal graft-vs-host disease (GVHD) occurred in 52% of the engrafted patients. The one-year survival rate for all patients was 44% (64/144). Among the one-year survivors, the primary disease was apparently cured in 90% and improved in 10%. Thus far, four patients died one to five years after transplant. Of the 60 patients currently alive, ten have chronic GVHD and the remainder are in good health. Multivariate analyses of the data disclosed a number of pretransplant factors associated with engraftment, GVHD, and one-year survival. The most important finding was that the use of male donors was preferable to female donors because of a higher rate of engraftment, less severe GVHD, and a higher one-year survival rate. (<i>JAMA</i>1981;245:1132-1139)
Grand Rounds
Authors: Giulio Bognolo
Journal: BMJ (2004)

Published by e-med (www.e-med.org.uk) www.grandrounds-e-med.com Rating: ![Graphic][1]</img>![Graphic][2]</img> This online journal aims to collect case reports from surgical and medical specialties in a unique database, providing information and education on new diseases, unusual features, and complications of treatment. Grand Rounds presents cases in a concise but clear manner. The editors, who claim that the medical literature undervalues the importance of case reports, plan to … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif
Characterization of Tumor-Suppressive Function of <i>SOX6</i> in Human Esophageal Squamous Cell Carcinoma
Authors: Yan-Ru Qin, Hong Tang, Fajun Xie, Haibo Liu, Yinghui Zhu, Jiaoyu Ai, Leilei Chen, Yan Li, Dora L. Kwong, Li Fu, Xin-Yuan Guan
Journal: Clinical Cancer Research (2010)

Abstract Purpose: By using cDNA microarray analysis, we identified a transcriptional factor, SOX6, was frequently downregulated in esophageal squamous cell carcinoma (ESCC). The aim of this study is to investigate the role of SOX6 in human esophageal cancer development, and to examine the prevalence and clinical significance of SOX6 downregulation in ESCC. Experimental Design: Expressions of SOX6 mRNA in 50 ESCCs and SOX6 protein in 300 ESCCs were investigated by semiquantitative RT-PCR and immunohistochemistry, respectively. The tumor-suppressive function of SOX6 was characterized by cell growth, foci formation, wound-healing and cell invasive assays, and tumor xenograft experiment. Western blot analysis was applied to detect protein expression levels. Results: SOX6 was frequently downregulated in primary ESCCs in both mRNA level (29/50, 58%) and protein level (149/219, 68.0%), which was significantly associated with the poor differentiation (P = 0.029), lymph node metastases (P = 0.014), advanced TNM stage (P = 0.000), and disease-specific survival (P &amp;lt; 0.001). Multivariate analysis indicated that the downregulation of SOX6 (P = 0.000) was a significant independent prognostic factors for ESCC. Functional studies showed that SOX6 was able to suppress both in vitro and in vivo tumorigenic ability of ESCC cells. The tumor-suppressive mechanism of SOX6 was associated with its role in G1/S cell-cycle arrest by upregulating expressions of p53 and p21WAF1/CIP1 and downregulating expressions of cyclin D1/CDK4, cyclin A, and β-catenin. Conclusions: We provided the first evidence that SOX6 is a novel tumor-suppressor gene in ESCC development and is a potential prognostic marker in ESCC. Clin Cancer Res; 17(1); 46–55. ©2010 AACR.
17-Allylamino-17-Demethoxygeldanamycin (17-AAG) abrogates the G2/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
Authors: A. N. Tse, D. Solit, N. Rosen, G. Schwartz
Journal: Journal of Clinical Oncology (2004)

3069 Background: AAG is an inhibitor of the molecular chaperone Hsp90 currently in clinical trials. Treatment with AAG causes a proteosome-dependent degradation of key oncogenic proteins e.g. Her2, raf1, Akt and cdk4 in tumors. Chk1 is a protein kinase critical for the G2/M cell cycle checkpoint and has recently been shown to be a target for AAG. We evaluated the activity of combining AAG with SN38 (SN), an active metabolite of irinotecan, in colon cancer cells. We hypothesized that tumors defective in the G2/M checkpoint by lacking p53 will be more sensitive to the combination. Methods: Parental (p53+/+) and p53-null (p53-/-) HCT116 colon cancer cells were treated with clinically achievable concentrations of SN (20 nM) and AAG (500 nM) in various sequences. Cells were analyzed for apoptosis and cell cycle progression; chk1 expression was measured in these cells and in the peripheral blood lymphocytes (PBLs) of patients treated with AAG and docetaxel in a separate ongoing phase I trial. Results: Single agent SN and AAG resulted in minimal apoptosis (<4%) in both cell lines. A significant enhancement of apoptosis was demonstrated in p53-/- cells exposed to either concurrent (SN+AAG) or sequential (SN◊AAG) treatment (12% and 27%, respectively); no enhancement was seen in p53+/+ cells. Treatment with SN alone resulted in a complete G2 arrest with <1% mitosis whereas concurrent or sequential treatment in p53-/- cells resulted in a marked increase in mitosis (31% and 78%, respectively), indicating that AAG abrogated the SN-induced G2 arrest. We also confirmed that AAG treatment resulted in a time- and dose-dependent depletion of chk1 but not chk2, another key G2/M checkpoint regulator. Chk1 protein was undetectable in pre-treatment PBLs. Conclusions: AAG inhibits the chk1-mediated G2/M checkpoint and potently enhances the cytotoxicity of SN selectively in p53-/- cells. Our results justify the initiation of a phase I study combining AAG and irinotecan, especially for patients with mutant p53. The lack of chk1 in PBL argues against its use as a pharmacodynamic surrogate. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Conforma
Substitutes for whole milk
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Structure of an alanine transfer ribonucleic acid
Authors: R. W. Holley
Journal: JAMA (1965)

The structures of nucleic acids are especially interesting and important because they provide specificity and enable nucleic acids to carry out many vital functions. Recently, work in our laboratories has led to the first determination of the chemical structure of a nucleic acid.<sup>1-4</sup>A brief summary of the work is given in this paper. The structure that was determined was that of an alanine transfer ribonucleic acid (RNA). Transfer RNAs function as specific carriers of activated amino acids, and during protein synthesis they interact with other cellular components (ribosomes and messenger RNA) to determine the structure of the protein that is being synthesized. (For a review of protein synthesis, see Moldave.<sup>5</sup>) In comparison with other nucleic acids, transfer RNAs are relatively small molecules. It seemed possible, therefore, some seven years ago, when our work was undertaken, that transfer RNAs might be amenable to detailed structural analysis. <h3>Isolation of</h3>
The authors reply
Authors: J. M Downey
Journal: Cardiovascular Research (1992)

Journal Article The authors reply Get access James M Downey James M Downey Department of Physiology, University of South Alabama Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 26, Issue 12, December 1992, Pages 1226–1227, https://doi.org/10.1093/cvr/26.12.1226a Published: 01 December 1992
Table of Contents
Authors: Hiroshi Nishi, Masaomi Nangaku, M Wetzels, Jai Radhakrishnan, Ranjan Das, Soo-Jin Kim, Thi Nguyen, Ju Kwon, Seung-Kuy Cha, Kyu-Sang Park, Yusuke Okabayashi, Shinya Nagasaka, Go Kanzaki, Nobuo Tsuboi, Takashi Yokoo, Akira Shimizu, Kerstin Ebefors, Robert Wiener, Liping Yu, Evren Azeloglu, Zhengzi Yi, Fu Jia, Weijia Zhang, Margaret Baron, John He, Börje Haraldsson, Ilse Daehn, Manuela Colucci, Rita Carsetti, Maria Rosado, Simona Cascioli, Maurizio Bruschi, Giovanni Candiano, Giorgia Corpetti, Laura Giardino, Jessica Serafinelli, Chiara Giannone, Gian Ghiggeri, Maria Rastaldi, Roberto Sitia, Francesco Emma, Marina Vivarelli
Journal: Kidney International (2019)
A Psychiatric Milestone.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report on an Investigation Into the Causes of Maternal Mortality in the City of Madras: Being a Report on the Investigation of 436 Maternal Deaths That Occurred During a Twelve-Month Period in the City of Madras
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arch Biochemistry and Biophysics, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blind. A Story of These Times.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum factor from patients with cirrhosis and hepatocellular carcinoma enhances production of prostaglandin E2 by U937 cells
Authors: H Iwamoto
Journal: Hepatology (1991)

The effect of serum from patients with cirrhosis and hepatocellular carcinoma on the release of prostaglandin E2 by the human histiocytic lymphoma cell line U937 was investigated to explain the mechanism underlying the immunoregulatory dysfunction of monocytes in cirrhosis and hepatocellular carcinoma. Prostaglandin E2 production by U937 cells cultured with serum from cirrhosis patients (5.9 ± 2.7 ng/ml, p < 0.01) and hepatocellular carcinoma patients (5.4 ± 2.6 ng/ml, p < 0.01) was significantly higher than that of control cultures (2.0 ± 1.0 ng/ml). This activity was decreased after heating and after freezing and thawing. By size exclusion fast protein liquid chromatography, the probable factor was eluted in the fraction with a molecular weight of 150 kD. By anion exchange chromatography with a stepwise increase of the NaCl concentration, the peak activity augmenting prostaglandin E2 production by U937 cells was eluted in the 0.05 to 0.1 mol/L NaCl fraction. The high level of this factor (monocyte-regulating factor) in patient serum might be one cause of abnormal monocyte immunoregulatory function in cirrhosis and hepatocellular carcinoma. (HEPATOLOGY 1991;14:1123–1128.)
Vaccine Information Pamphlets
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome
Authors: P.C.M. KERKHOF, P.M. STEIJLEN, R.A.P. RAYMAKERS
Journal: British Journal of Dermatology (1996)

Acrodermatitis continua of Hallopeau (ACH) is a rare manifestation of pustular psoriasis which may considerably disable affected patients.In this case report we confirm the efficacy of acitretin in the treatment of ACH and, in addition, describe the course of the myelodysplastic syndrome (MDS) from which the patient was suffering.During acitretin treatment, there was a transformation into acute myeloid leukaemia.We discuss the effect of retinoids on the bone marrow of normal subjects, patients with AIDS, and patients with acute myeloid leukaemia.Our experience in the present case, and the information from the available literature, lead us to advise against the use of the aromatic retinoids, acitretin and etretinate, in patients with MDS.If such treatment is indicated, intensive haematological supervision is mandatory.Acrodermatitis continua of Hallopeau (ACH) is a rare type of localized pustular psoriasis.The condition is characterized by the occurrence of pustules on the fingers and toes.Systemic antipsoriatic treatments are indicated in ACH.Although no controlled studies are available, ACH is reported to respond well to systemic cortico-1_Q steroids, methotrexate, acitretin, and cyclosporin.Recently, we have treated a patient with ACH, who also had a myelodysplastic syndrome (MDS) with a refractory anaemia (RA) and a severe thrombocyto penia.The severity of the ACH necessitated systemic treatment, and the patient was given acitretin with careful monitoring of the blood parameters.
Expansion of Philadelphia Chromosome–Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice
Authors: Christine Hoyle, Charles D. Bangs, Pearl Chang, Onsi Kamel, Bela Mehta, Robert S. Negrin
Journal: Blood (1998)
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
Authors: R. Postina
Journal: Journal of Clinical Investigation (2004)

During the preparation of this manuscript for publication, an error was introduced into the Results section, in the fourth sentence of the paragraph beginning with "The levels of the APP-derived soluble peptides Aβ40 and Aβ42 in brains of double-transgenic mice and APP [V717I] control animals at the age of 18 weeks were quantified by specific sandwich ELISAs."The correct sentence appears below.We regret this error.In line ADAM10-mo × APP [V717I] , Αβ40 and Aβ42 were reduced by 49% and 20%, and in line ADAM10-hi × APP [V717I] , by 39% and 29%, respectively.
Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: Activation of hepatic stellate cells as an early event
Authors: C Sempoux
Journal: Hepatology (1997)

Radiation-induced liver disease is recorded as a form of veno-occlusive disease. Its pathogenesis remains unclear even if the initial injury likely occurs in the endothelial cells of central veins. The aim of our study was to investigate liver morphological features in relation to α-isoform of smooth muscle actin expression in hepatic stellate cells in six patients treated by localized radiotherapy on the biliopancreatic area. Within the month after completion of treatment, an activation of hepatic stellate cells strictly confined to irradiated areas and coinciding with congestive changes was observed. At a later stage, collagen deposition gradually increased, replacing the congestive and destroyed areas. This new fibrotic tissue also contained numerous α-smooth muscle positive cells. Our data suggest that early hepatic stellate cells activation coinciding with congestive changes plays an important role in radiation liver injury and ensuing fibrosis.
Acute Hematogenous Prosthetic Joint Infection: Prospective Evaluation of Medical and Surgical Management
Authors: D. RodrÃ­guez, C. Pigrau, G. Euba, J. Cobo, J. GarcÃ­a-Lechuz, J. Palomino, M. Riera, M. D. del Toro, A. Granados, X Ariza
Journal: Clinical Microbiology and Infection (2009)
Complications of intestinal bypass for obesity
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal